Total submissions: 7
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV000820715 | SCV000961439 | uncertain significance | not provided | 2025-01-30 | criteria provided, single submitter | clinical testing | This sequence change replaces proline, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 125 of the NTHL1 protein (p.Pro125Leu). This variant is present in population databases (rs777263711, gnomAD 0.1%). This variant has not been reported in the literature in individuals affected with NTHL1-related conditions. ClinVar contains an entry for this variant (Variation ID: 662952). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
| Ambry Genetics | RCV001021037 | SCV001182600 | uncertain significance | Hereditary cancer-predisposing syndrome | 2023-08-22 | criteria provided, single submitter | clinical testing | The p.P125L variant (also known as c.374C>T), located in coding exon 2 of the NTHL1 gene, results from a C to T substitution at nucleotide position 374. The proline at codon 125 is replaced by leucine, an amino acid with similar properties. This amino acid position is well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
| Gene |
RCV000820715 | SCV002104455 | uncertain significance | not provided | 2024-07-15 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Identified in an individual with cancer (PMID: 34871433); This variant is associated with the following publications: (PMID: 34871433) |
| Sema4, |
RCV001021037 | SCV002528962 | uncertain significance | Hereditary cancer-predisposing syndrome | 2021-08-10 | criteria provided, single submitter | curation | |
| Center for Genomic Medicine, |
RCV003321751 | SCV004027048 | uncertain significance | not specified | 2025-03-04 | criteria provided, single submitter | clinical testing | |
| Baylor Genetics | RCV003467499 | SCV004192099 | uncertain significance | Familial adenomatous polyposis 3 | 2023-10-15 | criteria provided, single submitter | clinical testing | |
| Quest Diagnostics Nichols Institute San Juan Capistrano | RCV000820715 | SCV004222202 | uncertain significance | not provided | 2024-11-02 | criteria provided, single submitter | clinical testing | The NTHL1 c.374C>T (p.Pro125Leu) variant has not been reported in individuals with NTHL1-related conditions in the published literature. The frequency of this variant in the general population, 0.0009 (9/10010 chromosomes (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is uninformative in the assessment of its pathogenicity. Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded predictions that this variant is benign. Based on the available information, we are unable to determine the clinical significance of this variant. |